BR112023020442A2 - Inibidor da protease 1 específica de ubiquitina (usp1) - Google Patents
Inibidor da protease 1 específica de ubiquitina (usp1)Info
- Publication number
- BR112023020442A2 BR112023020442A2 BR112023020442A BR112023020442A BR112023020442A2 BR 112023020442 A2 BR112023020442 A2 BR 112023020442A2 BR 112023020442 A BR112023020442 A BR 112023020442A BR 112023020442 A BR112023020442 A BR 112023020442A BR 112023020442 A2 BR112023020442 A2 BR 112023020442A2
- Authority
- BR
- Brazil
- Prior art keywords
- usp1
- inhibitor
- ubiquitin
- specific protease
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 title 2
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940095049 Ubiquitin-specific protease inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
inibidor da protease 1 específica de ubiquitina (usp1). divulga um composto de fórmula (i) como um inibidor de usp1, ou um sal farmaceuticamente aceitável do mesmo, uma composição farmacêutica compreendendo o composto ou o sal farmaceuticamente aceitável do mesmo e uso do mesmo na prevenção ou tratamento de doenças associadas a usp1.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110403760 | 2021-04-09 | ||
CN202110829701 | 2021-07-22 | ||
CN202111166322 | 2021-09-30 | ||
CN202111591747 | 2021-12-23 | ||
CN202210242231 | 2022-03-11 | ||
PCT/CN2022/085703 WO2022214053A1 (zh) | 2021-04-09 | 2022-04-08 | 泛素特异性蛋白酶1(usp1)抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023020442A2 true BR112023020442A2 (pt) | 2023-11-21 |
Family
ID=83545106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023020442A BR112023020442A2 (pt) | 2021-04-09 | 2022-04-08 | Inibidor da protease 1 específica de ubiquitina (usp1) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4321515A1 (pt) |
JP (1) | JP2024513554A (pt) |
KR (1) | KR20230170658A (pt) |
CN (1) | CN117136189A (pt) |
AU (1) | AU2022253524A1 (pt) |
BR (1) | BR112023020442A2 (pt) |
CA (1) | CA3213709A1 (pt) |
TW (1) | TW202304933A (pt) |
WO (1) | WO2022214053A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3235765A1 (en) | 2021-11-12 | 2023-05-19 | Jianping Wu | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
TW202327602A (zh) * | 2021-11-12 | 2023-07-16 | 香港商英科智能有限公司 | 泛素特異性蛋白酶1 (usp1)之小分子抑制劑及其用途 |
WO2023148643A1 (en) * | 2022-02-03 | 2023-08-10 | Aurigene Oncology Limited | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
WO2023208130A1 (zh) * | 2022-04-29 | 2023-11-02 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
CN117003757A (zh) * | 2022-05-07 | 2023-11-07 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为usp1抑制剂 |
WO2024006879A1 (en) * | 2022-06-29 | 2024-01-04 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
WO2024041634A1 (zh) * | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | 三环类化合物及其应用 |
WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
WO2024094170A1 (zh) * | 2022-11-04 | 2024-05-10 | 深圳晶泰科技有限公司 | 泛素特异性蛋白酶1的抑制剂及其应用 |
CN116768906B (zh) * | 2023-05-29 | 2024-04-09 | 遵义医科大学珠海校区 | 一种三并环化合物及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330989A (en) * | 1991-10-24 | 1994-07-19 | American Home Products Corporation | Heterocycles substituted with biphenyl-3-cyclobutene-1,2-dione derivatives |
GB9125842D0 (en) * | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
WO1995018616A2 (en) * | 1994-01-03 | 1995-07-13 | Acea Pharm Inc | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
JPH08325248A (ja) * | 1995-05-26 | 1996-12-10 | Chugoku Kayaku Kk | テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法 |
WO2014086737A1 (de) * | 2012-12-06 | 2014-06-12 | Bayer Cropscience Ag | Kondensierte 2-pyridon-3-carboxamide und ihre verwendung als herbizide |
TWI733652B (zh) * | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
SG11201804901WA (en) * | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
CA3066939A1 (en) * | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
-
2022
- 2022-04-08 CN CN202280024236.1A patent/CN117136189A/zh active Pending
- 2022-04-08 JP JP2023560334A patent/JP2024513554A/ja active Pending
- 2022-04-08 TW TW111113413A patent/TW202304933A/zh unknown
- 2022-04-08 BR BR112023020442A patent/BR112023020442A2/pt unknown
- 2022-04-08 EP EP22784119.4A patent/EP4321515A1/en active Pending
- 2022-04-08 AU AU2022253524A patent/AU2022253524A1/en active Pending
- 2022-04-08 KR KR1020237033597A patent/KR20230170658A/ko unknown
- 2022-04-08 CA CA3213709A patent/CA3213709A1/en active Pending
- 2022-04-08 WO PCT/CN2022/085703 patent/WO2022214053A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW202304933A (zh) | 2023-02-01 |
CN117136189A (zh) | 2023-11-28 |
JP2024513554A (ja) | 2024-03-26 |
KR20230170658A (ko) | 2023-12-19 |
AU2022253524A1 (en) | 2023-10-12 |
WO2022214053A1 (zh) | 2022-10-13 |
CA3213709A1 (en) | 2022-10-13 |
EP4321515A1 (en) | 2024-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
MX2022015812A (es) | Inhibidores de cisteina proteasas y sus metodos de uso. | |
DOP2002000438A (es) | Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
PA8432901A1 (es) | Compuestos de piridilpirrol | |
AR060089A1 (es) | Tratamiento del dolor | |
AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
CL2020002891A1 (es) | Nuevos derivados de quinolina | |
ES2174921T3 (es) | Inhibidores de la proteasa del vih. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
BR112022014861A2 (pt) | Métodos de tratamento para deficiência de alfa-1 antittripsina | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
CR20220199A (es) | Inhibidores del factor d del complemento para administración oral | |
CL2021002217A1 (es) | Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda | |
PH12020551772A1 (en) | Oxo-substituted compound | |
HRP20090022T3 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences | |
BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
PA8525801A1 (es) | Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 | |
ES2177671T3 (es) | Benzamida enterocinetica. | |
ECSP045405A (es) | Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa |